HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $45

Benzinga Newsdesk www.benzinga.com Positive 76.5%

Neg 0% Neu 0% Pos 76.5%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $40 to $45.